Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alliance for Aging Research Waxman/Hatch Position Mirrors BIO Stance

Executive Summary

The Alliance for Aging Research's support of patent restoration for clinical development time echoes BIO's position on Waxman/Hatch Act reform.

You may also be interested in...



Generic Litigation Costs Estimated To Be $150-$300 Mil. This Year

Generic drug-related litigation costs will be between $150 mil. and $300 mil. during 2000, attorney Robert Green (Leydig, Voit and Mayer, Chicago) told the UBS Warburg specialty pharmaceuticals conference in New York City May 24.

Generic Litigation Costs Estimated To Be $150-$300 Mil. This Year

Generic drug-related litigation costs will be between $150 mil. and $300 mil. during 2000, attorney Robert Green (Leydig, Voit and Mayer, Chicago) told the UBS Warburg specialty pharmaceuticals conference in New York City May 24.

Waxman/Hatch Debate Moves Forward: Generic Biologics Not Ruled Out

A generic approval process for biological product is being recognized as one item for consideration in reform of the Waxman/Hatch Act by the law's key sponsor in the Senate.

UsernamePublicRestriction

Register

PS035779

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel